Form 4: Alnylam Director Michael W. Bonney Acquires Stock Options

Director Michael W. Bonney reports acquisition of stock options in Alnylam Pharmaceuticals.

Summary

• On May 16, 2024, Michael W. Bonney, a director of Alnylam Pharmaceuticals, acquired 5,228 stock options.
• The exercise price of these options is $151.22.
• The options vest in full on the earlier of May 16, 2025, or the date of retirement or resignation, provided such date occurs no more than 90 days prior to May 16, 2025.
• Following the transaction, Bonney directly owns 5,228 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition, which doesn't inherently indicate positive or negative sentiment, but the acquisition itself can be seen as a sign of confidence.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests a commitment from the director to the company's long-term success.

Industry Context

This is a routine disclosure related to insider transactions, common in publicly traded companies to ensure transparency and compliance with securities regulations.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates